2 active not recruiting, 1 completed. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 2, Completed 1 |
| Phase 1 | 1 | Completed 1 |
Follow CDX-1127: new trials by email Literature Review of CDX-1127 trials Research Report on CDX-1127
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer Atezolizumab, Biopsy, Biospecimen Collection - Metastatic Distal Bile Duct Adenocarcinoma, Metastatic Gallbladder Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 57 | 2021-12-15 | 2025-05-23 |
| Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas Nivolumab, Varlilumab - ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 54 | 2018-12-21 | 2026-10-26 |
| Vaccination With 6MHP, With or Without Systemic CDX-1127, in Patients With Stage II-IV Melanoma 6MHP, Montanide ISA-51, polyICLC - Melanoma | Phase 1 / Phase 2 | Completed | Craig L Slingluff, Jr | 33 | 2018-11-13 | 2024-02-06 |
Burkitt Lymphoma (1) · Cholangiocarcinoma (1) · Gallbladder Neoplasms (1) · Lymphoma, B-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Primary Effusion (1) · Lymphomatoid Granulomatosis (1) · Melanoma (1) · Plasmablastic Lymphoma (1)
National Cancer Institute (NCI) (2) · Craig L Slingluff, Jr (1)
United States (3)
Craig L Slingluff, Jr., MD (1) · Nilofer S Azad (1) · Stephen M Ansell (1)
UM1CA186686 (1), UM1CA186691 (1), UM1CA186709 (1)